Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
The National Institutes Of Biomedical Innovation Health And Nutrition currently faces 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. The prosecution is notably decentralized, involving distinct examiners and 3 distinct art units. This means every active case is being reviewed by a different examiner in a different specialized unit.
CHONG, KIMBERLY is the busiest examiner with 1 pending case, which is consistent with the even distribution across the examiners. With the pending office actions spread across the art units, the applicant must navigate separate sets of examiner preferences. The 1 pending case per examiner requires a tailored approach for each specific art unit involved.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §102 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHONG, KIMBERLY | 1 | 72.4% | +13.0% |
| SZNAIDMAN, MARCOS L | 1 | 37.3% | +16.2% |
| FRUMKIN, JESSE P | 1 | 69.9% | +48.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17789402 | METHOD AND SYSTEM FOR ESTIMATING RENAL FUNCTION | FRUMKIN, JESSE P | 22d |
| 17905442 | PREVENTION OR TREATMENT OF ANEURYSMS USING MIR-33B INHIBITOR | CHONG, KIMBERLY | 34d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17789402 | METHOD AND SYSTEM FOR ESTIMATING RENAL FUNCTION | FRUMKIN, JESSE P | 22d |
| 17905442 | PREVENTION OR TREATMENT OF ANEURYSMS USING MIR-33B INHIBITOR | CHONG, KIMBERLY | 34d |
| 17789399 | D-SERINE TRANSPORT MODIFIER AND SCREENING METHOD THEREOF, AND SCREENING METHOD OF D-SERINE TRANSPORTER PROTEIN | SZNAIDMAN, MARCOS L | — |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| 1628 | 1 |
| 1685 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17905442 | PREVENTION OR TREATMENT OF ANEURYSMS USING MIR-33B INHIBITOR | CHONG, KIMBERLY | 1636 | §103§112 | Non-Final OA | 34d | Pending | Sep 01, 2022 |
| 17789399 | D-SERINE TRANSPORT MODIFIER AND SCREENING METHOD THEREOF, AND SCREENING METHOD OF D-SERINE TRANSPORTER PROTEIN | SZNAIDMAN, MARCOS L | 1628 | §102 | Final Rejection | — | Pending | Jun 27, 2022 |
| 17789402 | METHOD AND SYSTEM FOR ESTIMATING RENAL FUNCTION | FRUMKIN, JESSE P | 1685 | §101§102§103 | Final Rejection | 22d | Pending | Jun 27, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial